Evaluation of HIV viral load turnaround time in Moshi, Tanzania.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
30 09 2022
Historique:
received: 15 10 2020
accepted: 16 03 2021
entrez: 12 10 2022
pubmed: 13 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

Viral load measurement is an important gold standard for monitoring anti-retroviral treatment among people living with human immunodeficiency virus. The optimal use of the viral load results for guiding antiretroviral therapy depends on timely availability of the results at the clinic. The objective of the current study was to evaluate the turnaround time and utilization of viral load results in the clinical decision process. This was a retrospective cohort study which involved patients receiving cART from 1 August 2018 to 31 January 2017 at three clinics in Tanzania. Data was extracted from patient files at the clinics and relevant records were kept at the viral load determining laboratory. The data were analysed with the Statistical Package for Social Sciences version 20. 445 subjects had a viral load in test results and 88% had a viral load of > 1,000 copies/mL. The median duration on the current regimen was five years. Median time between the clinics receiving the results and communicating them to the patients was 40 days. Shorter turnaround time was observed for patients with virological failure (p = 0.003). A higher prevalence of virological failure was found in patients monitored at the Kilimanjaro Christian Medical Centre (KCMC) compared to the two primary health clinics (p = 0.04). The median viral load turnaround time was longer than stipulated by the national Tanzanian guidelines. Interventions that may reduce viral load turn-around-time, including point of care viral load testing, are needed to optimise monitoring of anti-retroviral therapy.

Identifiants

pubmed: 36223627
doi: 10.3855/jidc.14145
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1500-1505

Informations de copyright

Copyright (c) 2022 Elizabeth L Moirana, Eva Prosper Muro, Ireen Eliah Kiwelu, James Kimaro, Rachel Manongi, Zahra Theilgaard, Terese L Katzenstein.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Auteurs

Elizabeth L Moirana (EL)

Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

Eva Prosper Muro (EP)

Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania. e.muro@kcri.ac.tz.

Ireen Eliah Kiwelu (IE)

Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

James Kimaro (J)

Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

Rachel Manongi (R)

Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

Zahra Theilgaard (Z)

Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Terese L Katzenstein (TL)

Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH